Suitable efficacy models to aid in the discov- ery of novel treatments.

There is a major unmet need in the treatment of asthma which is growing in incidence and prevalence in industrialized countries. The prevalence of asthma has doubled in the Western world over the previous 20 years. In addition to the estimated 180,000 asthma related deaths per year, there is a substantial economic burden due to lost school/work days and increased medical costs.


Allergic asthma is typically triggered by allergens in the air such as pollen, mold, dust mites etc and is  commonly characterized by reversible airway destruction, elevated levels of IgE causing mast cell activation, chronic airway inflammation and airway hyper-responsiveness (AHR). The immunological processes involved are characterized by proliferation and activation of Th2 lymphocytes, setting off an allergic  cascade. Treatments currently available act by dampening inflammation or relaxing airways but do not alter  underlying pathology and disease exacerbations still occur. These facts highlight the need for novel treatments, which in turn require suitable efficacy models.


This whitepaper discusses the events underlying the disease as well as standard readout options and corresponding data.